Abstract
The life science informatics marketplace--known as bioinformatics--is set to
expand as high-tech companies infiltrate this arena and biopharmaceutical
companies incorporate key informatic solutions into their business strategies.
TriMark Publications believes that many of the segments of bioinformatics
described in this report offer an unusual opportunity for accelerated
expansion within the coming years. This study is arranged to provide an
overview of bioinformatics market segments and offer evidence that these
segments are poised for significant future growth. Each segment is accompanied
by analysis and forecasts by product type and application.
This analysis surveys the bioinformatics market and the latest information
regarding emerging new products and industry trends. The study will quantify
and qualify the bioinformatics market segments as an area of research, product
development and investment. Forecasts of the bioinformatics market and an
analysis of products in the worldwide information-processing market will
provide a basis for understanding the significance of past developments and
future possibilities within this market category.
The main objectives of this analysis are as follows:
- Identify viable technology drivers through a comprehensive look at various
platform technologies for segments of the bioinformatics market.
- Impart a complete understanding of the chief bioinformatics tools and
their predictive, screening, prognostic, monitoring, pharmacogenomic and
product value, from basic principles to application.
- Distinguish feasible market opportunities via identifying high-growth
applications in different bioinformatics areas, with a focus on the biggest
and fastest expanding markets for diagnosis and treatment of diseases.
- Focus on global industry development through an in-depth analysis of the
major world markets for bioinformatics, including forecasts for growth.
- Present market figures regarding the current value of the bioinformatics
market, projections and growth rates. The source of this information is the
most current data derived from the global diagnostic industry.
Methodology
The author of this report is a Ph.D. in biochemistry from the University of
Minnesota, with many decades of experience in scientific writing and as a
medical industry analyst. He has been a senior director of several large
regional and national healthcare laboratories. The senior editor is a Ph.D. in
physiology with a focus on computational physiology from the University of
Toronto in Canada, with postdoctoral training and experience in cell and
systems biology from the University of Toronto. The editor is a Ph.D. in
biomedical sciences with a focus in microbiology from Meharry Medical College
in Nashville, TN, with postdoctoral training and experience in molecular and
cell biology as well as computational analysis obtained at the University of
Pittsburgh, the National Institutes of Health and, most recently, at the
Walter Reed Army Institute of Research.
Company-specific information is obtained mainly from industry trade
publications, academic journals, news and research articles, press releases
and corporate websites, as well as annual reports for publicly-held firms.
Additionally, sources of information include the non-governmental
organizations (NGOs) such as the World Health Organization (WHO) and
governmental entities like the U.S. Department of Health and Human Services
(HHS) and U.S. federal agencies such as National Institutes of Health (NIH),
Food and Drug Adminstration (FDA) and the Centers of Disease Control and
Prevention (CDC). Where possible and practicable, the most recent data
available have been used.
Some of the statistical information was taken from Biotechnology Associates'
databases and from TriMark' s private data stores. The information in this
study was obtained from sources that we believe to be reliable, but we do not
guarantee the accuracy, adequacy or completeness of any information or
omission or for the results obtained by the use of such information. Key
information from the business literature was used as a basis to conduct
dialogue with and obtain expert opinion from market professionals regarding
commercial potential and market sizes. Senior managers from major company
players were interviewed for part of the information in this report.
Primary Sources
TriMark collects information from hundreds of Database Tables and many
comprehensive multi-client research projects, as well as Sector Snapshots that
we publish annually. We extract relevant data and analytics from TriMark' s
research as part of this data collection.
Secondary Sources
TriMark uses research publications, journals, magazines, newspapers,
newsletters, industry reports, investment research reports, trade and industry
association reports, government-affiliated trade releases and other published
information as part of its secondary research materials. The information is
then analyzed and translated by the Industry Research Group into a TriMark
study. The Editorial Group reviews the complete package with product and
market forecasts, critical industry trends, threats and opportunities,
competitive strategies and market share determinations.
Table of Contents
1. Overview
- 1.1 Statement of Report
- 1.2 About this Report
- 1.3 Scope of this Report
- 1.4 Methodology
- 1.5 Executive Summary
2. Introduction
- 2.1 Global Bioinformatics Products Industry
- 2.2 Computers and Biology
- 2.3 Bioinformatics and the Internet
- 2.4 Company Evaluation Overview
- 2.5 Market Outlook
- 2.6 Competitive Structure
- 2.7 Applications of Bioinformatics
- 2.7.1 Medicine
- 2.7.2 Microbial Genomics
- 2.7.3 Agriculture
- 2.8 R&D
- 2.8.1 Allocation of R&D
- 2.8.2 Traditional Drug Discovery Process
- 2.8.3 Drug Discovery and Bioinformatics
- 2.8.4 Collaborative Agreements
- 2.9 The Human Genome Project (HGP)
- 2.9.1 Goals of the Human Genome Project
- 2.9.2 Benefits of the Human Genome Project
- 2.10 Barriers to Entry
- 2.11 Proteomics and Databases
- 2.11.1 Protein Database Standards
- 2.11.2 Future Trends
3. The U.S. Bioinformatics Market
- 3.1 Overview
- 3.2 Market Restraints and Drivers
- 3.2.1 Market Restraints
- 3.2.2 Market Drivers
4. Genomics
- 4.1 The Biotechnology Industry
- 4.2 The Development of a Genomics Market
- 4.2.1 Market Drivers
- 4.2.2 Market Restraints
- 4.2.3 Market Size and Growth Projections
- 4.2.4 The U.S. Genomics Market
- 4.3 Biochips and DNA Microarrays
- 4.3.1 Key Challenges
- 4.3.2 Freeware
- 4.3.3 New Tools
- 4.4 Bioinformatics
- 4.5 Disease Targets
- 4.6 Functional Genomics
- 4.7 Gene Sequencing
- 4.8 Gene Sequence Variation Detection
- 4.9 Comparative Genomics
- 4.10 Genome Database Arrays
- 4.11 High-throughput Genomics
- 4.11.1 High-throughput Technology
- 4.11.2 Lab on a Chip
- 4.12 Pharmacogenomics
- 4.13 Probe Arrays
- 4.13.1 Gene Expression Monitoring Arrays
- 4.13.2 DNA Analysis Arrays
- 4.14 Proteomics
- 4.15 Sequencing
- 4.16 Single Nucleotide Polymorphisms (SNPs)
- 4.17 Structural Genomics
- 4.18 Photolithography
- 4.19 Instrumentation
5. The Bioinformatics Industry
- 5.1 Definition and Role of Bioinformatics
- 5.1.1 Bioinformatics Sector Overview
- 5.1.2 The Future Status of Bioinformatics
- 5.1.3 Barriers to Growth
- 5.2 Types of Data and Bioinformatics Applications
- 5.2.1 Validated Core Modeling Technology
- 5.2.2 Broad Applicability
- 5.2.3 Data Management Compliant with Industry Standards
- 5.2.4 Open Architecture
- 5.2.5 Ease of Use
- 5.2.6 Increased Access
- 5.3 Functions of Bioinformatics Software
- 5.3.1 Data Management
- 5.3.2 Data Transformation
- 5.3.3 Data Collaboration
- 5.3.4 Interface for Online Data Sources
- 5.4 Target Markets for Informatics Software
- 5.5 Steps Involved in Bringing a Drug to Market
- 5.6 Costs Incurred in Developing a New Drug
- 5.7 Industry Drivers and Challenges
- 5.8 Industry Risks
- 5.9 Products of Bioinformatics
- 5.10 Bioinformatics Processes
- 5.11 Informatics Tools and Functionalities
- 5.11.1 Sequence to Structure
- 5.11.2 Lead Identification and Optimization
- 5.11.3 Development and Formulation
- 5.11.4 Improving Materials and Processes
- 5.11.5 Other Materials-Based Industries
- 5.12 Role of Bioinformatics in the Biotechnology Value Chain
- 5.13 Bioinformatics Market Segment
- 5.13.1 Databases
- 5.13.2 Hardware
- 5.13.3 Software
- 5.13.4 Bioinformatics Services
- 5.14 Bioinformatics Market Size
- 5.14.1 Sales and R&D
- 5.14.2 IT Budget
- 5.14.3 Projected Bioinformatics Market Size
- 5.15 Global Market Perspective
6. Bioinformatics Business
- 6.1 Bioinformatics Business Models
- 6.1.1 Changing Business Models
- 6.1.2 Competition for Pure Play Informatics Companies
- 6.1.3 Non-Profit Organizations
- 6.1.4 In-House Bioinformatics Solutions
- 6.1.5 Large IT Companies
- 6.2 Bioinformatics Target Disciplines
- 6.2.1 Comparative Genomics
- 6.2.2 Pharmacogenomics
- 6.2.3 Functional Genomics
- 6.2.4 Proteomics
- 6.2.5 Structural Genomics
- 6.2.6 Image Informatics
- 6.2.7 Clinical Trial Informatics
- 6.2.8 Cheminformatics
- 6.3 Bioinformatics Architecture
- 6.4 Bioinformatics Applications
- 6.4.1 Data Search Tools
- 6.4.2 Data Visualization Tools
- 6.4.3 Data Mining and Clustering
- 6.4.4 Enterprise Solutions
- 6.4.5 Data Warehousing
- 6.5 Evaluation of Bioinformatics Solutions
- 6.5.1 Requirements of Study
- 6.5.2 Shortlisting the Options
- 6.5.3 Scoring Patterns
- 6.5.4 Performance
- 6.5.5 Data Storage
- 6.5.6 Data Management in Drug Discovery
- 6.5.7 Key Issues in Bioinformatics Data Storage
- 6.6 Convergence of Industries
- 6.7 Proteins as a Driver
- 6.8 Current Bioinformatics Research
- 6.9 New Bioinformatics Modeling Algorithms
- 6.10 3D Modeling
- 6.11 Patenting Bioinformatics Algorithms
7. Recent Industry Activity
- 7.1 Collaborations and Acquisitions
- 7.2 Product Development and Launches
8. Corporate Profiles
- 8.1 Abbott Laboratories
- 8.2 Abgenix
- 8.3 Ablynx
- 8.4 Accelrys
- 8.5 Affimed Therapeutics
- 8.6 Affitech
- 8.7 Affymetrix
- 8.8 Agencourt Bioscience Corporation
- 8.9 Agensys
- 8.10 Agilent Technologies
- 8.11 Alexion Pharmaceuticals
- 8.12 AlgoNomics
- 8.13 ALLEZ Software
- 8.14 Amgen
- 8.15 Antisoma
- 8.16 Applied Biosystems
- 8.17 Arana Therapeutics
- 8.18 Ariadne Genomics
- 8.19 Array Genetics
- 8.20 Astellas Pharma
- 8.21 AstraZeneca
- 8.22 Automated Handling Systems
- 8.23 Avesthagen, Limited
- 8.24 Bioalma
- 8.25 BIOBASE Biological Databases
- 8.26 BioCarta
- 8.27 Biodatabases (AMITA Corporation)
- 8.28 BioDiscovery
- 8.29 Biogen Idec
- 8.30 BioInformatics
- 8.31 BioInformatics Services
- 8.32 BioInformatics Solutions
- 8.33 Biomax Informatics
- 8.34 BioServe Technologies
- 8.35 Biosiris
- 8.36 BioSoftSolutions
- 8.37 Biotique Systems
- 8.38 BioInvent International
- 8.39 Biosite Discovery
- 8.40 BioWa
- 8.41 BioWisdom
- 8.42 Bio-Xtal
- 8.43 Boehringer Ingelheim
- 8.44 Cambridge Antibody Technology Group
- 8.45 Capital Genomix
- 8.46 Celera Group
- 8.47 Cellectis
- 8.48 Cellomics
- 8.49 CeuticalSoft
- 8.50 Chemical Computing Group
- 8.51 Cimarron Software
- 8.52 CLONDIAG Chip Technologies
- 8.53 CodonCode Corporation
- 8.54 CompuDrug International
- 8.55 Compugen USA
- 8.56 Corimbia
- 8.57 Crucell
- 8.58 CSIRO Bioinformatics
- 8.59 CuraGen Corporation
- 8.60 CyberGene
- 8.61 Cytogen
- 8.62 Data Unlimited International
- 8.63 deCODE Genetics
- 8.64 Decodon
- 8.65 Deltagen
- 8.66 Digilab
- 8.67 DNA Software
- 8.68 DNAPrint Genomics
- 8.69 DNA Star
- 8.70 DxS
- 8.71 Dyax Corp.
- 8.72 Eisai
- 8.73 Elan Corporation
- 8.74 Electric Genetics Corporation
- 8.75 Elusys Therapeutics
- 8.76 Entagen
- 8.77 Entelos
- 8.78 Enzon Pharmaceuticals
- 8.79 Epigenomics
- 8.80 ePitope Informatics
- 8.81 EraGen Biosciences
- 8.82 European Bioinformatics Institute (EBI) Industry Programme
- 8.83 Evolutionary BioInformatics
- 8.84 Genamics
- 8.85 GeneData
- 8.86 Gene Logic
- 8.87 Genentech
- 8.88 Geneva Bioinformatics (GeneBio)
- 8.89 Genmab
- 8.90 GenOdyssee
- 8.91 Genolyze
- 8.92 Genomatica
- 8.93 GenomeQuest
- 8.94 Genomic Solutions
- 8.95 Genomining
- 8.96 Genovac
- 8.97 Genzyme
- 8.98 Geospiza
- 8.99 GlaxoSmithKline
- 8.100 Glycominds
- 8.101 Health Discovery Corporation
- 8.102 Hitachi Corporate Technology Group
- 8.103 IBM Life Sciences
- 8.104 ImClone Systems
- 8.105 ImmunoGen
- 8.106 Immunomedics
- 8.107 Improved Outcomes Software
- 8.108 INCOGEN
- 8.109 Incyte Corporation
- 8.110 Informagen
- 8.111 Ingenuity Systems
- 8.112 InNexus Biotechnology
- 8.113 Insilicos
- 8.114 Intrexon Corporation
- 8.115 Invitrogen Corporation
- 8.116 IO Informatics
- 8.117 Johnson & Johnson
- 8.118 LabVantage Solutions
- 8.119 Lexigen
- 8.120 Lifespan Biosciences
- 8.121 Lion Bioscience
- 8.122 MathEcology
- 8.123 Matrix Science
- 8.124 Medarex
- 8.125 Medicel
- 8.126 MedImmune
- 8.127 Merus
- 8.128 METabolic Explorer
- 8.129 Metahelix Life Sciences
- 8.130 Metalife
- 8.131 Micromet
- 8.132 Millennium Pharmaceuticals
- 8.133 Molecular Connections
- 8.134 Molecular Networks
- 8.135 Molecularware
- 8.136 MorphoSys
- 8.137 Nexus Genomics
- 8.138 Nonlinear Dynamics
- 8.139 Novartis
- 8.140 Ocimum Biosolutions
- 8.141 OmniViz
- 8.142 Partek
- 8.143 PDL BioPharma
- 8.144 Perlegen Sciences
- 8.145 Philogen
- 8.146 Philotec
- 8.147 Prokaria
- 8.148 Quantiom Bioinformatics
- 8.149 Relevant Software
- 8.150 Roche
- 8.151 Rosetta Inpharmatics
- 8.152 Sanofi-Aventis
- 8.153 SBI Science
- 8.154 Seascape Learning
- 8.155 Seattle Genetics
- 8.156 Scil Proteins
- 8.157 Simulations Plus
- 8.158 Spotfire
- 8.159 Strand Life Sciences
- 8.160 Sun Microsystems
- 8.161 Symphogen
- 8.162 Syngene
- 8.163 Tahoe Informatics
- 8.164 Tanox
- 8.165 3rd Millennium
- 8.166 ThromboGenics
- 8.167 Thomson Reuters
- 8.168 TIB MOLBIOL
- 8.169 Trion Pharma
- 8.170 Tripos
- 8.171 UBI Life Sciences
- 8.172 Viventia Biotech
- 8.173 VizX Labs
- 8.174 Wyeth
- 8.175 Xcellerex
- 8.176 Xencor
- 8.177 Xoma
- 8.178 Xpogen
INDEX OF FIGURES
- Figure 4.1: Representation of Biotechnology Market, Geographically, 2008
- Figure 5.1: Informatics Applications along the Drug-Discovery Value Chain
- Figure 5.2: Functions of Bioinformatics Software in Research
- Figure 5.3: EMBL Database Growth, 1995-2008
- Figure 5.4: The Steps Involved in Bringing a Drug to Market
- Figure 5.5: The Breakdown of Total Costs in New Drug Development, 2007
- Figure 5.6: The Role of Bioinformatics in the Biotechnology Value Chain
- Figure 5.7: Worldwide Pharmaceutical Sales and R&D Expenditures, 2000-2013
- Figure 5.8: Worldwide Growth in IT Budget, 2000-2013
- Figure 5.9: Worldwide Bioinformatics Market, 2000-2013
- Figure 6.1: Steps of a Proteomics Experiment
- Figure 6.2: Bioinformatics Architecture
INDEX OF TABLES
- Table 2.1: Leading Biotechnology Companies
- Table 2.2: Total of Domestic U.S. R&D, 2006-2013
- Table 2.3: Global Biotechnology Market, 2007
- Table 2.4: SIB Informatics Databases
- Table 4.1: The U.S. Biotechnology Industry Size and Revenue, 2000-2007
- Table 4.2: Global Biotechnology Industry Major Segments
- Table 4.3: Genomics Sector Market Size, 2006-2013
- Table 4.4: Total Biochip Market, 2007-2013
- Table 4.5: Selected Competitors in the Biochip Market
- Table 4.6: Biochip Microarray Products
- Table 4.7: Bioinformatics Tools
- Table 4.8: Functional Genomics Companies Building Advanced Integrated
Platforms and Substantial Databases
- Table 4.9: Companies Using New Genomic Tools
- Table 4.10: Non-DNA-Based Chip Suppliers
- Table 4.11: Robotics or "Lab-on-a-Chip" Market Sector
- Table 4.12: Key High-throughput and Systemic Approaches in Genomic Analysis
- Table 4.13: Pharmacogenomics Segment Players
- Table 4.14: The Worldwide Market for Pharmacogenomics, 2006-2013
- Table 4.15: Competitors in the SNP Genotyping Segment
- Table 4.16: Scanning and Detection Technology Suppliers
- Table 5.1: Data Sources and Bioinformatic Investigations
- Table 5.2: Drivers and Challenges of the Bioinformatics Industry
- Table 5.3: Bioinformatics Activities, Sub-Activities and Key Players
- Table 5.4: Bioinformatics Market Size, 2006-2013
- Table 5.5: Cheminformatics Market Size, 2006-2013
- Table 5.6: In-silico Informatics Market Size, 2006-2013
- Table 5.7: Bioinformatics Hardware and Systems Market Size, 2006-2013
- Table 6.1: Alliances between IT/Telecom and Biotechnology Firms
- Table 6.2: Types of Intellectual Property Protection for Bioinformatics
Tools
|
相關報告
|
